Anemos Bio

Today’s patients, shaping tomorrow’s treatments.

We’re solving clinical trial failure by building the world’s largest living collection of cancer cells from real patients, so next-gen therapeutics can be tested on tumors that reflect the modern patient, before the first trial.

Our Story

At 49, I was diagnosed with Stage 4 lung cancer. The cancer became resistant to standard therapy after 15 months of treatment.

I needed more data about my cancer. A repeat biopsy did two things: it empowered me with a trove of next generation sequencing information, and it gave my colleagues living cancer cells to grow in the lab. These cells enable testing of thousands of existing and new therapeutics which would be impossible to do in a single patient.

We will revolutionize the development of treatments for cancer with hundreds of these cell lines from real people like me available for advanced testing and analysis.

Our approach has the potential to save hundreds of thousands of lives.

Models that reflect the patients they’re meant to treat.

The biological, data, and AI infrastructure to test and inform new therapies, so that every patient has a treatment that works for them.

Current

Built continuously from patients diagnosed today.

Previously treated

Drawn from every line of care, including tumors that have become resistant to therapy.

Diverse

Across ancestry, sex, age, and smoking history, including never-smokers.

True to the tumor

Each cell line is profiled alongside the tumor it came from, so we can show it still matches.

01The Anemos Atlas

Living cancer cells grown from patient tumors, across every subtype and stage of treatment.
02The data

Whole-genome sequencing, single-cell RNA sequencing, spatial transcriptomics, spatial proteomics, surfaceome profiling, and drug response, for each cell line and its original tumor.
03The AI

Trained on our data to predict who will respond to a drug, which targets matter, and how to improve drug candidates.

Every prediction is tested back in the Anemos Atlas, and the results train the next round.

Whole-genome sequencing — Spatial transcriptomics

A new standard for testing cancer drugs.

Models: Decades-old cell lines that have drifted far from the tumors they came from; Models from today’s patients, verified to stay true to their original tumor
Representation: Never-smokers and non-European patients are barely represented; Models across ancestry, sex, age, and smoking history
Resistance: Resistant tumors are rarely modeled, so drugs for later lines lag behind; Models from every line of treatment, so new drugs can target cancers that have evolved to resist treatment
Matching: Patients cycle through drugs by trial and error; Evidence of which patients each drug works for, before they take it
Outcome: 9 in 10 cancer drugs fail in clinical trials; Most failures caught in the lab, before trials begin

Today’s patients, shaping tomorrow’s treatments.

Our Story

90% of cancer drugs fail in clinical trials. A major driver is inaccurate and narrow preclinical models.

Slash failure rates. Save lives.